The Netherlands And Ghent

ROTTERDAM, the Netherlands and GHENT, Belgium, December 1, 2011 - Funds will be Used to Progress Differentiated Therapeutic Antibody Programs into Clinical Development arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announced today the closing of a EUR 27.5 million (USD 37 million) Series B fundraising round, which was oversubscribed.